scholarly journals ‘Triple Clear’: A Systematic and Up-to-Date Surgical Process for Giant Cell Tumor of Bone Graded Companacci II and III with or without Pathological Fracture and Joint Invasion

2021 ◽  
Author(s):  
Yushan Wang ◽  
Qiaoqiao Tian ◽  
Haoze Li ◽  
Jian Li ◽  
Peng Ren ◽  
...  
Keyword(s):  
Giant Cell ◽  
Analogue Scale ◽  
Pathological Fracture ◽  
Operating Time ◽  
Bone Grafts ◽  
Cell Tumor ◽  
Clinical Effects ◽  
Recurrence Rates ◽  
Giant Cell Tumours

Abstract Objectives: 1) To describe a systematic process for giant cell tumours of bone (GCTB). 2) To compare the clinical effects of ‘triple clear’ (TC) and segmental resection (SR), bone grafts and bone cement.Method: Patients with primary GCTB graded Companacci II and III who were treated with either SR (n = 39) or TC (n = 41) were included. The pain level was determined by the Visual Analogue Scale. Limb function was determined by the Musculoskeletal Tumour Society (MSTS) score.Result: The operating time was 135.7±38.4 min in the TC group and 174.2±43.0 min in the SR group (P<0.05). The recurrence rates were 7.3% and 10.0%, respectively (P = 0.37). The MSTS scores at three months after surgery were 19.8±1.5 in the TC group and 18.8±1.5 in the SR group. The MSTS scores at two years were 26.3±0.7 and 24.2±1.6, respectively (P＜0.05).Conclusion: TC is recommended for GCTB graded Companacci II-III and GCTB accompanied by pathological fracture or joint invasion. Bone grafts may be more suitable than bone cement in the long term.

scholarly journals Giant Cell Tumor of Bone: Oncological and Functional Results of Long-term Follow-up

1998 ◽  
Vol 28 (5) ◽  
pp. 323-328 ◽  
Author(s):  
Y. Oda ◽  
H. Miura ◽  
M. Tsuneyoshi ◽  
Y. Iwamoto
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Functional Results ◽  
Cell Tumor ◽  
Long Term Follow Up

Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab

2014 ◽  
Vol 14 (7) ◽  
pp. e15-e21 ◽  
Author(s):  
Tobias A. Mattei ◽  
Edwin Ramos ◽  
Azeem A. Rehman ◽  
Andrew Shaw ◽  
Shreyasumar R. Patel ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Complete Regression

scholarly journals Giant Cell Tumor: A Rare Condition in the Immature Skeleton—A Retrospective Study of Symptoms, Treatment, and Outcome in 16 Children

Sarcoma ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Thale M. Asp Strøm ◽  
Anette Torød Skeie ◽  
Ingvild Koren Lobmaier ◽  
Olga Zaikova
Keyword(s):  
Retrospective Study ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Rare Condition ◽  
Functional Results ◽  
Cell Tumor ◽  
Initial Symptom ◽  
Recurrence Rates ◽  
Intralesional Curettage ◽  
Immature Skeleton

Background. Pediatric giant cell tumor (GCT) of bone is rare and the course of the disease in the immature skeleton is sparsely described. We performed a retrospective study addressing symptoms, treatment, and outcome in children with GCT.Methods. Review of medical records and images of patients with GCT. Patients were detected from our hospital prospective database and those with open epiphyseal cartilages were included.Results. 16 children (75% girls) from 6 to 15 years old were identified. Eight lesions (50%) were in long bones and 4 (25%) in flat bones. One lesion appeared to be purely epiphyseal. All patients had pain as the initial symptom. Local recurrence developed in 2 patients. 14 of 16 patients returned to normal activity with no sequelae. One patient developed anisomelia after surgery.Conclusions. The biological tumor behavior in children does not seem to differ from what is reported in adults. Lesions in flat bones are very unusual, but our data alone do not provide enough evidence to conclude that this is more common in the immature skeleton. Literature review showed only one previous case report describing a purely epiphyseal GCT. Intralesional curettage is appropriate treatment and gives good functional results with acceptable recurrence rates.

scholarly journals THE MORPHOLOGICAL FEATURES OF VARIANTS OF GIANT CELL TUMOR STRUCTURE

2010 ◽  
Vol 16 (1) ◽  
pp. 139-145
Author(s):  
M. Yu. Zaytseva ◽  
Ph. Yu. Zasulsky
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Treatment Approach ◽  
Cell Tumor ◽  
Long Term Results ◽  
Results Of Treatment ◽  
Morphological Criteria ◽  
Histopathologic Feature

The morphological criteria of giant cell tumor and the different ways of the run of the disease were designated as the result of collation between the histopathologic feature with the clinicoradiographic dates and the long-term results of treatment of 101 of patients. These findings promote a better collaboration of pathologist and surgeons. In future these results could be used for creating an algorithm of determination of the surgery extent and treatment approach.

scholarly journals Clinical effects of three surgical approaches for a giant cell tumor of the distal radius and ulna

2016 ◽  
Vol 5 (5) ◽  
pp. 613-617 ◽  
Author(s):  
Jing Zhang ◽  
Yi Li ◽  
Dongqi Li ◽  
Junfeng Xia ◽  
Su Li ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Distal Radius ◽  
Cell Tumor ◽  
Surgical Approaches ◽  
Clinical Effects

scholarly journals Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study

2017 ◽  
Vol 28 ◽  
pp. v645-v646 ◽  
Author(s):  
E. Palmerini ◽  
J-Y. Blay ◽  
A. Le Cesne ◽  
P. Reichardt ◽  
P. Rutkowski ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Phase 2 ◽  
Open Label ◽  
Term Efficacy ◽  
Phase 2 Study ◽  
Open Label Phase

A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up

2011 ◽  
Vol 42 (5) ◽  
pp. 727-733 ◽  
Author(s):  
Tsuyoshi Saito ◽  
Hiroyuki Mitomi ◽  
Hiroshi Izumi ◽  
Yoshiyuki Suehara ◽  
Taketo Okubo ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
P53 Mutation ◽  
Cell Tumor ◽  
Long Term Follow Up ◽  
Malignant Giant Cell Tumor

scholarly journals Locally Aggressive Connective Tissue Tumors

2018 ◽  
Vol 36 (2) ◽  
pp. 202-209 ◽  
Author(s):  
Mrinal M. Gounder ◽  
David M. Thomas ◽  
William D. Tap
Keyword(s):  
Connective Tissue ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Predictive Biomarkers ◽  
Cell Tumor ◽  
Loss Of Function ◽  
Recurrence Rates ◽  
End Points ◽  
Bladder Obstruction ◽  
Patient Reported

In this review, we highlight the complexities of the natural history, biology, and clinical management of three intermediate connective tissue tumors: desmoid tumor (DT) or aggressive fibromatosis, tenosynovial giant cell tumor (TGCT) or diffuse-type pigmented villonodular synovitis (dtPVNS), and giant cell tumor of bone (GCTB). Intermediate histologies include tumors of both soft tissue and bone origin and are locally aggressive and rarely metastatic. Some common aspects to these tumors are that they can be locally infiltrative and/or impinge on critical organs, which leads to disfigurement, pain, loss of function and mobility, neurovascular compromise, and occasionally life-threatening consequences, such as mesenteric, bowel, ureteral, and/or bladder obstruction. DT, PVNS, and GCTB have few and recurrent molecular aberrations but, paradoxically, can have variable natural histories. A multidisciplinary approach is recommended for optimal management. In DT and PVNS, a course of observation may be appropriate, and any intervention should be guided by symptoms and/or disease progression. A surgical approach should take into consideration the infiltrative nature, difficulty in obtaining wide margins, high recurrence rates, acute and chronic surgical morbidities, and impact on quality of life. There are similar concerns with radiation, which especially relate to optimal field and transformation to high-grade radiation-associated sarcomas. Systemic therapies must be considered carefully in light of acute and chronic toxicities. Although standard and novel therapies are promising, many unanswered questions, such as duration of therapy and optimal end points to evaluate efficacy of drugs in clinical practice and trials, exist. Predictive biomarkers and novel clinical trial end points, such as volumetric measurement, magnetic resonance imaging T2 weighted mapping, nuclear imaging, and patient-reported outcomes, are in development and will require validation in prospective trials.

Sign in / Sign up

Export Citation Format

Share Document